WO2012071480A3 - Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging - Google Patents

Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging Download PDF

Info

Publication number
WO2012071480A3
WO2012071480A3 PCT/US2011/061972 US2011061972W WO2012071480A3 WO 2012071480 A3 WO2012071480 A3 WO 2012071480A3 US 2011061972 W US2011061972 W US 2011061972W WO 2012071480 A3 WO2012071480 A3 WO 2012071480A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
adiposity
cosmetic treatment
lipophilic
bulging
Prior art date
Application number
PCT/US2011/061972
Other languages
French (fr)
Other versions
WO2012071480A2 (en
Inventor
John Daniel Dobak
Kenneth Walter Locke
Original Assignee
Lithera, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lithera, Inc. filed Critical Lithera, Inc.
Publication of WO2012071480A2 publication Critical patent/WO2012071480A2/en
Publication of WO2012071480A3 publication Critical patent/WO2012071480A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/63—Steroids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q90/00—Cosmetics or similar toiletry preparations for specific uses not provided for in other groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Abstract

sProvided herein are pharmaceutical and cosmetic formulations and methods for regional adiposity reduction, and aesthetic treatment of contour defects such as abdominal bulging; comprising an injectable formulation comprising: (a) active ingredient that consists essentially of an adipose tissue-reducing amount of one or more lipophilic glucocorticosteroids, or salts, solvates, or polymorphs thereof; and (b) one or more subcutaneously acceptable inactive ingredients.
PCT/US2011/061972 2010-11-24 2011-11-22 Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging WO2012071480A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41709210P 2010-11-24 2010-11-24
US61/417,092 2010-11-24

Publications (2)

Publication Number Publication Date
WO2012071480A2 WO2012071480A2 (en) 2012-05-31
WO2012071480A3 true WO2012071480A3 (en) 2012-08-02

Family

ID=45475500

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/061972 WO2012071480A2 (en) 2010-11-24 2011-11-22 Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging

Country Status (2)

Country Link
GB (1) GB2485886A (en)
WO (1) WO2012071480A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019008493A2 (en) 2016-10-28 2019-07-09 SpineThera pharmaceutical compositions and uses thereof
CN111184688B (en) * 2020-03-10 2021-09-17 成都天台山制药有限公司 Dexamethasone acetate injection and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20070014843A1 (en) * 2005-07-14 2007-01-18 Dobak John D Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20080300229A1 (en) * 2005-11-30 2008-12-04 Galderma S.A. Sprayable pharmaceutical compositions comprising a corticoid and an oily phase
US20100093690A1 (en) * 2002-02-28 2010-04-15 Ian Bruce 5-phenylthiazole derivatives and use as pi3 kinase inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2077830T3 (en) * 2006-10-17 2013-04-30 Lithera Inc Methods, compositions, and formulations for the treatment of thyroid eye disease
US9132084B2 (en) * 2009-05-27 2015-09-15 Neothetics, Inc. Methods for administration and formulations for the treatment of regional adipose tissue
EP2523667A4 (en) * 2010-01-15 2014-04-02 Lithera Inc Lyophilized cake formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20100093690A1 (en) * 2002-02-28 2010-04-15 Ian Bruce 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US20070014843A1 (en) * 2005-07-14 2007-01-18 Dobak John D Sustained release enhanced lipolytic formulation for regional adipose tissue treatment
US20080300229A1 (en) * 2005-11-30 2008-12-04 Galderma S.A. Sprayable pharmaceutical compositions comprising a corticoid and an oily phase

Also Published As

Publication number Publication date
GB201120091D0 (en) 2012-01-04
WO2012071480A2 (en) 2012-05-31
GB2485886A (en) 2012-05-30

Similar Documents

Publication Publication Date Title
WO2012160180A3 (en) Pharmaceutical composition for administration to nails
MX369121B (en) Aqueous pharmaceutical formulation of tapentadol for oral administration.
WO2010088000A3 (en) Antifibrotic compounds and uses thereof
EP3659585A4 (en) Composition for delivering physiologically active ingredients into blood vessel
MX2011008616A (en) Peptides used in the treatment and/or care of the skin, mucous membranes and/or scalp and their use in cosmetic or pharmaceutical compositions.
IL222578A0 (en) Method for preparing pharmaceutical compositions intended for oral administration comprising one or more active ingredients and the compositions comprising same
EP3626253A3 (en) Stable formulations of linaclotide
EP2889027A3 (en) Oral preparation, injection preparation, external skin preparation and cosmetic method for preventing or improving wrinkles
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
WO2013178965A3 (en) Active ingredients activating mitophagy in skin cells and use of same for improving skin condition
WO2012161497A3 (en) Peptide derivatives having a superior moisturizing effect and uses thereof
BR112015007592A2 (en) enalapril compositions
WO2012130820A3 (en) Isopentyl esters for the use in cosmetic, dermatological, or pharmaceutical compositions
EP2361083A4 (en) Composition for treatment of epithelial tissue
EP4053154A4 (en) Keratin bd-10, preparation method therefor, and pharmaceutical composition thereof, and use thereof
MX353580B (en) Monounsaturated fatty acid for preventing and/or treating skin complexion imperfections.
WO2010119366A3 (en) A medicinal cream made using fluticasone propionate, and chitosan, and a process to make the same
WO2012074856A3 (en) Selective, lipophilic, and long-acting beta agonist monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2012071480A3 (en) Lipophilic glucocorticosteroid monotherapeutic formulations and methods for the cosmetic treatment of adiposity and contour bulging
WO2011139249A3 (en) Pharmaceutical composition comprising cefdinir
BR112012021445B8 (en) pharmaceutical or neutroceutical formulation, and use of a bioavailability promoting agent
MX2014014579A (en) O/w-emulsion-type topical pharmaceutical compositions containing a retinoid.
WO2012143857A8 (en) Combination of carotenoid, phytooestrogen and vitamin c for moisturizing the skin
WO2015100348A8 (en) Keloid reduction using topical allantoin
EP2570131A4 (en) Formulation against leishmaniasis and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11843296

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11843296

Country of ref document: EP

Kind code of ref document: A2